Gynecologic cancer
12 articles shown
When Two Hospitals Give Different Answers to How Long Chemotherapy Lasts After Recurrence — Fixed Cycles vs. Maintenance Therapy, and the Platinum-Free Interval
After a recurrence, chemotherapy often shifts from a fixed number of cycles to treatment continued while the response lasts, which makes any single duration hard to state. Maintenance drugs carry different trial-defined durations and insurance rules, so one hospital may say a year and another two and a half. This piece explains what those numbers include and which questions to ask in clinic.
When your doctor says you can stop the blood thinner after a year — how long cancer-associated clots are treated, and why anemia and bleeding risk enter the decision
Cancer can shift the blood toward clotting, and clots are usually treated with anticoagulants for at least three to six months — often longer while the cancer is active. A decision to stop weighs a stable, organized clot against rising bleeding risk such as falling hemoglobin or lesions that can bleed. Here is what to clarify at the clinic, including recurrence warning signs and how the drug is handled around procedures.
Facing a Risk-Reducing Oophorectomy Before Natural Menopause: What Surgical Menopause Changes, and How to Plan Ahead for Bone and Heart Health
For people facing risk-reducing salpingo-oophorectomy before natural menopause after a BRCA finding: how surgical menopause differs from natural menopause, which short-term symptoms and long-term bone and cardiovascular issues are monitored, and how hormone and non-hormonal options, lifestyle steps and baseline tests are typically planned with a care team.
When Two Cycles of Chemo Make Her Feel Well Again — Understanding Interval Debulking Surgery and the Cancer You Cannot See
Explains why surgery may still be recommended in advanced ovarian cancer even when a patient feels dramatically better after neoadjuvant chemotherapy — covering the difference between symptom relief and remaining disease, the purpose and timing of interval debulking surgery, prehabilitation before an operation, cautions about substituting complementary care for the treatment schedule, and questions to bring to clinic.
When the Fever Keeps Coming Back After the First Chemotherapy Cycle — Why a Temperature That Drops With Fever Medicine Is Not the Same as Getting Better
Fever arising 7–14 days after a first chemotherapy cycle coincides with the neutrophil nadir and may represent febrile neutropenia, a time-sensitive emergency. This article explains why a temperature that falls with antipyretics is not the same as resolution, why fever can recur after treatment in the emergency department, how to keep a useful home fever log, and which signs warrant immediate contact with the care team.
Seeking a Second Opinion at Another Hospital After Surgery: What Records Matter More Than Fear of Being Turned Away
When seeking a second opinion at another hospital after surgery elsewhere, complete records — referral letter, operative and pathology reports, imaging, and borrowed pathology slides — matter more than fear of being turned away. Recommendations on adjuvant chemotherapy can differ between centers, especially for rare tumors, and for older or frail patients the discussion often includes adjusting intensity rather than a simple yes or no.
Thinking About New Health Indemnity Insurance Years After Cancer Treatment — Underwriting for Prior Conditions, Disclosure Duties, and Exclusion Periods
A plain-language guide to considering indemnity medical insurance years after cancer treatment: how indemnity differs from fixed-benefit cover, why preventive screening is often excluded, what simplified underwriting for applicants with a medical history involves, why full disclosure protects you, how exclusion riders can remove the coverage you most expected, and how to weigh it all against benefits you already hold.
When You Finish Chemo but Are Advised to Keep Taking a Pill — Understanding Maintenance Therapy, PARP Inhibitors, and How Biomarkers Like BRCA and HRD Guide Ovarian Cancer Treatment
A plain-language guide to what maintenance therapy means in ovarian cancer, how biomarkers such as BRCA and HRD help choose treatments like PARP inhibitors, and how to keep new-drug news in perspective.
When ovarian cancer returns 'within six months' — understanding why the time to recurrence separates 'platinum-sensitive' from 'platinum-resistant' disease
A plain-language explanation of platinum-based chemotherapy for high-grade serous ovarian cancer and why the time from finishing treatment to recurrence (the platinum-free interval) is used to distinguish 'platinum-sensitive' from 'platinum-resistant' disease. It clarifies that 'resistant' is not the patient's fault nor the end of treatment, and outlines what to discuss with a care team when choosing next steps.
When Chemo Is 'Weekly for Three Weeks, Then a Week Off' — Understanding Why Treatment Runs in Cycles and What the Rest Week Does
A plain-language look at why chemotherapy runs in cycles, what the rest week does for recovery and blood counts like neutrophils, how single-drug and combination regimens differ, and which side effects to watch for and report.
When Blood Sugar Swings During Cancer Treatment — Why Sleep, Stress, and Hormones Move Your Glucose, and the Diabetes Screenings (Eyes, Kidneys, Feet) That Are Easy to Miss
Why blood sugar becomes erratic during cancer treatment — sleep, hormonal shifts, steroids, and stress — the role of rest, and the diabetes complication screenings (eyes, kidneys, feet) that are easy to miss.
Appointments Booked at Several Hospitals, Unsure Which Specialist to Choose — Comparing Care Teams That Fit You Instead of Picking the Single 'Best' Doctor
When a suspected recurrence leaves you with appointments at several major hospitals, this piece explains how to compare care settings — multidisciplinary teams, relevant experience, and travel access — rather than hunting for a single 'best' doctor, and how hearing multiple opinions can ease the pressure of deciding.